This randomized clinical trial studies fluorine F 18 fluorodopa (F-DOPA) positron emission tomography (PET)/computed tomography (CT) in finding tumors in patients with suspected recurrence of glioblastoma. New diagnostic procedures, such as fluorine F 18 fluorodopa PET/CT, may help find and diagnose glioblastoma recurrence.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT01813877.
PRIMARY OBJECTIVES:
I. To determine whether fluorine F 18 fluorodopa (18F-FDOPA) imaging is more accurate than conventional imaging for detection of disease recurrence.
II. To assess the impact of 18F-DOPA imaging on patient management.
III. To determine whether the addition of 18F-DOPA to conventional imaging results in improved patient survival and reduced health care expenditures.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients undergo fluorine F 18 fluorodopa PET/CT. Patients also undergo standard of care diagnostic tests.
ARM II: Patients undergo standard of care diagnostic tests.
After completion of study treatment, patients are followed up for 36 months.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationUCLA / Jonsson Comprehensive Cancer Center
Principal InvestigatorJohannes Czernin
